Researchers are building on groundbreaking work published in 2019 that set the standard for treating patients who fail first-line therapy.
Category: Neuroscience Excellence
Research on how spreading depolarizations cause secondary injury in early recovery could be the tip of the iceberg in finding new treatments for a range of brain-related conditions.
Recent analysis from the SHINE trial has found a link between high blood sugar after thrombolysis and life-threatening brain bleeds, especially in patients with severe strokes.
Researchers believe understanding mutations in ER protein translocation and processing complexes will lead to improved treatments for patients with congenital disorders of glycosylation.
UVA Health's Pituitary Tumor Program ensures optimal patient outcomes through collaboration, cutting-edge techniques, and streamlined care pathways.
Two new brain tumor medications could make a significant difference in the way tumors are treated — and in the lives of patients.
Researchers in the Sontheimer lab study ways to slow memory loss in diseases like Alzheimer's by reducing inflammation in the brain.
Learn how a discovery in his lab is leading to novel therapeutics for autoimmune diseases and cancer.
Optimal cEEG monitoring time may go well beyond the standard 24 hours, UVA Health research reveals.
Treatment research from the Lukens Lab targets Alzheimer's, multiple sclerosis, and traumatic brain injury.